// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Current Factors Associated with Insufficient Vitamin D Status in Patients with Osteoporosis

Sandeep Dhillon - American College of Rheumatology (ACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

N/A

Ergocalciferol

Defining Alendronate Drug Holidays and Re-Initiation in US Medicare Data

Jeffrey R. Curtis - American College of Rheumatology (ACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Alendronate sodium

Defining Cutoffs Corresponding to Low Levels of Disease Activity in Psoriatic Arthritis, Using the Patient-Reported Psoriatic Arthritis Impact of Disease Questionnaire (PsAID12). an Analysis of 436 Patients

Clemence Gorlier - American College of Rheumatology (ACR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Improving the Efficiency of Heart Failure Care

Lisa D. Rathman - Heart Failure Society of America (HFSA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

The PARASAIL study- Patient Reported Outcomes from the Canadian Real World Experience use of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction

Haissam Haddad - Heart Failure Society of America (HFSA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Sacubitril/valsartan

Protein Losing Enteropathy in a Post-Cardiac Transplant Adult: A Case Report

Idris Bare - Heart Failure Society of America (HFSA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

Alpha 1-Antitrypsin

Why do clinicians withhold anticoagulation in patients with atrial fibrillation and CHA2DS2VASc score of 2 or higher?

D M Siegal - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

When are atrial fibrillation patients at risk to discontinue anticoagulation treatment? Results from the GLORIA-AF Registry

M Paquette - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Outcomes of stable coronary artery disease worldwide. Insights from the CLARIFY registry

E Sorbets - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Predictive value of VTE-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with venous thromboembolism: results of the XALIA study

F A Klok - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Cluster analysis of cardiovascular risk phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine

A Sharma - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Sitagliptin

Outcome after ross procedure in adult patients: a systematic review, meta-analysis and microsimulation

S Sibilio - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Diamond and Forrester-predicted vs. coronary CTA-observed prevalence of obstructive CAD in patients with stable chest pain: results from the PROMISE trial

B Foldyna - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

The high-risk ECG pattern of ST-elevation myocardial infarction: a substudy of the randomized trial of primary PCI with or without routine manual thrombectomy (TOTAL trial)

J Leivo - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Betablockers and outcomes in stable coronary artery disease. Insights from the CLARIFY registry

E Sorbets - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Diabetes and acute aortic dissection: insights from the International Registry of Acute Aortic Dissection

D Spinelli - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial

G Chi - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

betrixaban

Benefit of medical therapy versus revascularization in patients with stress myocardial perfusion single photon emission computed tomography: results from a large international registry

P Azadani - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Technetium (99mTc) sestamibi

A novel model for prediction of ischemic stroke in patients without atrial fibrillation

K Steensig - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Left atrial deformation in patients with moderate to severe aortic stenosis and heart failure

F Simard - European Society of Cardiology (ESC) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved